

# CORRECTIONS & AMENDMENTS

---

---

## CORRECTION

<https://doi.org/10.1038/s41586-018-0580-6>

## Author Correction: EZH2 inhibition sensitizes *BRG1* and *EGFR* mutant lung tumours to TopoII inhibitors

Christine M. Fillmore, Chunxiao Xu, Pooja T. Desai, Joanne M. Berry, Samuel P. Rowbotham, Yi-Jang Lin, Haikuo Zhang, Victor E. Marquez, Peter S. Hammerman, Kwok-Kin Wong & Carla F. Kim

Correction to: *Nature* <https://doi.org/10.1038/nature14122>, published online 28 January 2015.

We wish to correct two mutations in Supplementary Table 4 of this Letter. The NCI-H460 cell line was annotated as being mutant for *TP53*. NCI-H460 has been verified to be *TP53* wild type by several sources<sup>1</sup>. The NCI-H2009 cell line was annotated as being mutant for *PIK3CA*. As annotated by COSMIC (ref. 24 of the original Letter) and CCLE (ref. 25 of the original Letter), the NCI-H2009 cell line has a mutation in *PIK3C3*, rather than *PIK3CA*. The cell line is wild type for *PIK3CA*. The Supplementary Information of this Amendment contains the corrected Supplementary Table 4. These errors do not affect our conclusions. The original Letter has not been corrected.

**Supplementary information** is available in the online version of the Amendment.

1. Leroy, B. et al. Analysis of TP53 mutation status in human cancer cell lines: a reassessment. *Hum. Mutat.* **35**, 756–765 (2014).